IL-2 variants and uses thereof
By performing amino acid mutations on IL-2, it improves its thermal stability and reduces binding to non-regulatory T cells, and enhances the selective stimulation of regulatory T cells, it solves the problem of insufficient stability and binding ability of IL-2 drugs in the treatment of tumors and autoimmune diseases, achieving more effective therapeutic effects.
Patent Information
- Application Number
- JP2023515158
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-08-13
- Filing Date
- 2021-09-03
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2041-09-03
AI Technical Summary
The existing IL-2 drugs have insufficient stability and binding capacity of specific receptor complexes when treating tumors and autoimmune diseases, resulting in poor treatment results.
By designing and synthesizing IL-2 variants, specific amino acid mutations, such as Q13L, L18I, G27W, etc., the thermal stability of IL-2 is improved and the binding ability to non-regulatory T cells and natural killer cells is reduced, thereby enhancing the selective stimulation effect on regulatory T cells.
It improves the stability of IL-2 drugs and the ability to selectively stimulate regulatory T cells, and enhances the therapeutic effect on tumors and autoimmune diseases.
Smart Images

Figure 0007583155000033 
Figure 0007583155000034 
Figure 0007583155000035
Abstract
Description
[Technical field]
[0001] The present disclosure relates to the biomedical field, and in particular to IL-2 variants and uses thereof. [Background technology]
[0002] Interleukin 2 (IL-2) was originally identified as a T cell growth factor (TCGF), but subsequent studies have shown that it binds to receptors and promotes the proliferation and activation of immune cells such as T cells and NK cells.
[0003] IL-2 receptors include the IL-2Rα subunit (CD25), the IL-2Rβ subunit (CD122), and the IL-2Rγ subunit (CD132). Different subunits can form receptor complexes with different affinities, such as the high affinity receptor IL-2Rαβγ, the intermediate affinity receptor IL-2Rβγ, and the low affinity receptors IL-2Rα or IL-2Rαβ. Different cells express different types of IL-2R subunits. For example, resting conventional T cells (CD4 + T and CD8 + T cells normally express IL-2 receptor β (IL-2Rβ, CD122) and IL-2 receptor γ (IL-2Rγ, CD132) on the cell surface, but rarely express IL-2α receptor (IL-2Rα, CD25). However, in regulatory T cells (Treg), IL-2Rα is constitutively and highly expressed in addition to IL-2Rβ and IL-2Rγ.
[0004] Currently, researchers are attempting to use IL-2 or its variants to activate immune cells or subsets of immune cells to treat tumors or autoimmune diseases. For example, high-dose IL-2 has been approved for the treatment of malignant melanoma or metastatic renal cell carcinoma, and NKTR-358, a PEG-IL-2 conjugate, has been approved for clinical trials for autoimmune diseases. Summary of the Invention [Problem to be solved by the invention]
[0005] Therefore, improving the stability and yield of IL-2 and / or altering its binding ability to a specific receptor complex is of great importance for the development of IL-2 drugs. In view of this, the present disclosure is proposed. [Means for solving the problem]
[0006] The disclosure provides IL-2 variants, fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the variants or fusion proteins, IL-2 variants or fusion proteins prepared by the methods, pharmaceutical compositions, pharmaceutical uses, methods of treatment, and methods for preferentially stimulating regulatory T cells.
[0007] In a first aspect, the disclosure provides an IL-2 variant comprising one or more mutations at Q13, L18, G27, Y31, A73, H79, P82, I89, N90, V91, V93, F117, or R120 compared to wild-type IL-2.
[0008] In some particular embodiments, the mutation is a deletion, insertion or substitution, preferably a substitution.
[0009] In some specific embodiments, the IL-2 mutant comprises one or more of the following mutations: Q13L, L18I, G27W, Y31V, A73L, H79Q, P82L, I89L, N90Y, V91A, V93I, F117W, or R120F.
[0010] In some specific embodiments, the IL-2 variant comprises at least one mutation of groups (a) through (h): (a) A mutation at Y31 / A73 / H79; preferably a mutation at Y31V / A73L / H79Q; (b) a mutation at Q13; preferably a mutation at Q13L; (c) a mutation at R120; preferably a mutation at R120F; (d) a mutation at L18 / V91 / F117; preferably a mutation at L18I / V91A / F117W; (e) a mutation at L18 / I89 / V93; preferably a mutation at L18I / I89L / V93I; (f) a mutation at G27 / R120; preferably a mutation at G27W / R120F; (g) a mutation in P82 / R120; preferably a mutation in P82L / R120F; (h) A mutation at N90 / R120; preferably a mutation at N90Y / R120F.
[0011] In certain specific embodiments, the IL-2 variant has an amino acid sequence as set forth in any one of SEQ ID NO:2 to SEQ ID NO:9.
[0012] In certain embodiments, the Tm value of the IL-2 variant is higher than the Tm value of wild-type IL-2.
[0013] In certain specific embodiments, the wild-type IL-2 has the amino acid sequence shown in SEQ ID NO:60 or SEQ ID NO:1.
[0014] In some specific embodiments, the IL-2 mutant further comprises a mutation at H16, D20, N88, V91, or Q126, such as one or more mutations selected from the group consisting of H16E, D20A, D20H, D20Y, N88A, N88I, N88G, N88R, N88D, V91R, V91K, Q126L, or Q126F.
[0015] Preferably, the IL-2 variant further comprises at least one mutation selected from among groups (i) to (iv): (i) a mutation in H16; preferably a mutation in H16E; (ii) a mutation in D20; preferably a mutation in D20A; (iii) a mutation at V91; preferably a mutation at V91R; (iv) A mutation in H16 / V91; preferably a mutation in H16E / V91R.
[0016] In some specific embodiments, the IL-2 variant comprises at least one mutation of group (a) through group (n): (a) A mutation in H16 / Y31 / A73 / H79; preferably a mutation in H16E / Y31V / A73L / H79Q; (b) a mutation at H16 / R120; preferably a mutation at H16E / R120F; (c) a mutation in H16 / L18 / V91 / F117; preferably a mutation in H16E / L18I / V91A / F117W; (d) A mutation in H16 / L18 / I89 / V93; preferably a mutation in H16E / L18I / I89L / V93I; (e) A mutation at H16 / G27 / R120; preferably a mutation at H16E / G27W / R120F; (f) a mutation in H16 / P82 / R120; preferably a mutation in H16E / P82L / R120F; (g) A mutation at D20 / Y31 / A73 / H79; preferably a mutation at D20A / Y31V / A73L / H79Q; (h) a mutation at D20 / R120; preferably a mutation at D20A / R120F; (i) A mutation at V91 / Y31 / A73 / H79; preferably a mutation at V91R / Y31V / A73L / H79Q; (j) a mutation at V91 / Q13; preferably a mutation at V91R / Q13L; (k) a mutation at V91 / R120; preferably a mutation at V91R / R120F; (l) A mutation in V91 / L18 / I89 / V93; preferably a mutation in V91R / L18I / I89L / V93I; (m) A mutation in H16 / V91 / Y31 / A73 / H79; preferably a mutation in H16E / V91R / Y31V / A73L / H79Q; (n). A mutation in H16 / V91 / L18 / I89 / V93; preferably a mutation in H16E / V91R / L18I / I89L / V93I.
[0017] In some specific embodiments, the IL-2 variant has an amino acid sequence as set forth in any one of SEQ ID NO:22 to SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32 to SEQ ID NO:35, SEQ ID NO:37 or SEQ ID NO:38.
[0018] In certain embodiments, the IL-2 mutant further comprises one or more mutations selected from the group consisting of mutations at N26, N29, N30, N71, Q11, L132, L70, P82, G27, or F28.
[0019] Preferably, the IL-2 mutant further comprises one or more mutations selected from the group consisting of N26Q, N29S, N30S, N71Q, Q11C, L132C, L70C, P82C, G27C, or F78C.
[0020] More preferably, the IL-2 variant further comprises at least one group of mutations in groups (a) to (g): (a).N26Q; (b).N29S; (c).N30S; (d).N71Q; (e).Q11C / L132C; (f).L70C / P82C; (g).G27C / F78C.
[0021] In certain embodiments, the IL-2 mutant further comprises one or more mutations at F42, Y45, or L72, preferably selected from the group consisting of F42A, Y45A, or L72G.
[0022] In certain embodiments, the IL-2 mutant has a reduced ability to bind to the IL-2R βγ subunit complex compared to wild-type IL-2; preferably, the binding ability IL-2Rβγサブユニット複合体 / binding capacity IL-2αβγサブユニット複合体 is declining.
[0023] In certain embodiments, the variant has a reduced ability to stimulate non-regulatory T cells or NK (natural killer) cells compared to wild-type IL-2; the stimulation may be selected from intracellular STAT5 phosphorylation or cell proliferation.
[0024] In certain embodiments, the variant preferentially stimulates regulatory T cells (Treg) or T cell populations in peripheral blood over non-regulatory T cells or NK (natural killer) cells; the preferential stimulation can be selected from preferentially stimulating STAT5 phosphorylation in regulatory T cells, preferentially stimulating proliferation of regulatory T cells, increasing the ratio of regulatory T cells to non-regulatory T cells, or increasing the ratio of regulatory T cells to NK cells.
[0025] In a second aspect, the disclosure provides an IL-2 variant comprising one or more mutations at H16, D20, or V91 compared to wild-type IL-2; preferably, the IL-2 variant comprises at least one group of mutations selected from among groups (i) to (iv): (i) a mutation in H16; preferably a mutation in H16E; (ii) a mutation in D20; preferably a mutation in D20A; (iii) a mutation at V91; preferably a mutation at V91R; (iv) A mutation in H16 / V91; preferably a mutation in H16E / V91R.
[0026] In some specific embodiments, the IL-2 variant has the amino acid sequence shown in SEQ ID NO:21, SEQ ID NO:28, SEQ ID NO:31, or SEQ ID NO:36.
[0027] In certain embodiments, the IL-2 mutant further comprises one or more mutations selected from the group consisting of mutations at N26, N29, N30, N71, Q11, L132, L70, P82, G27, or F28.
[0028] Preferably, the IL-2 mutant further comprises one or more mutations selected from the group consisting of N26Q, N29S, N30S, N71Q, Q11C, L132C, L70C, P82C, G27C, or F78C.
[0029] More preferably, the IL-2 variant further comprises at least one group of mutations in groups (a) to (g): (a).N26Q; (b).N29S; (c).N30S; (d).N71Q; (e).Q11C / L132C; (f).L70C / P82C; (g).G27C / F78C.
[0030] In certain embodiments, the IL-2 mutant has a reduced ability to bind to the IL-2R βγ subunit complex compared to wild-type IL-2; preferably, the binding ability IL-2Rβγサブユニット複合体 / binding capacity IL-2αβγサブユニット複合体 is declining.
[0031] In certain embodiments, the variants have a reduced ability to stimulate non-regulatory T cells or NK (natural killer) cells compared to wild-type IL-2, which stimulation can be selected from intracellular STAT5 phosphorylation or cell proliferation.
[0032] In certain embodiments, the variant preferentially stimulates regulatory T cells (Tregs) or T cell populations in peripheral blood over non-regulatory T cells or NK cells; the preferential stimulation can be selected from preferentially stimulating STAT5 phosphorylation in regulatory T cells, preferentially stimulating proliferation of regulatory T cells, increasing the ratio of regulatory T cells to non-regulatory T cells, or increasing the ratio of regulatory T cells to NK cells.
[0033] In certain embodiments, the mutation comprises a deletion, insertion, or substitution, preferably a substitution.
[0034] In certain specific embodiments, the wild-type IL-2 has the amino acid sequence shown in SEQ ID NO:60 or SEQ ID NO:1.
[0035] In a third aspect, the present disclosure provides a fusion protein comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is an IL-2 variant as described above, and the second polypeptide is a non-IL-2 polypeptide.
[0036] In some specific embodiments, the second polypeptide is Fc, a tumor antigen binding molecule, or an IL-2 receptor subunit; The Fc is optionally a human IgG Fc, such as a human IgG1 Fc; Preferably, the human IgG1 Fc comprises at least one group of mutations selected from group (a) to group (i): (a).C220S; (b).N297G; (c).C220S and N297G; (d).A327Q; (e).L234A and L235A; (f).A287C and L306C; (g).A259C and L306C; (h).R292C and V302C; (i).V323C and I332C; More preferably, the Fc of human IgG1 has the amino acid sequence shown in SEQ ID NO:11; The tumor antigen optionally comprises EDB-FN (fibronectin extra domain), Muc1, p53, FAP, GD2, EpCAM, tenascin-C, CD20, CEA, MAdCAM-1, or WT1 (Wilms tumor protein 1); the tumor antigen binding molecule optionally comprises scFv, sdFv, Fab, Fab', F(ab') 2 or Fv; The IL-2 receptor subunit is optionally an IL-2 receptor alpha subunit.
[0037] In certain embodiments, the C-terminus of the first polypeptide is linked, with or without a linker, to the N-terminus of the second polypeptide; or the N-terminus of the first polypeptide is linked, with or without a linker, to the C-terminus of the second polypeptide; Preferably, the linker is (G 4 S) n , (GGNGT) n , or (YGNGT) n where n is selected from 1, 2, 3, 4, or 5; More preferably, the C-terminus of the first polypeptide is 4 S) 3 to the N-terminus of the second polypeptide by
[0038] In certain embodiments, the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NO:13 through SEQ ID NO:20 or SEQ ID NO:39 through SEQ ID NO:56.
[0039] In a fourth aspect, the present disclosure provides a conjugate comprising the variant or fusion protein described above, and further comprising a stabilizer, drug, or tracer molecule bound to the variant or fusion protein; the stabilizer may be selected from polyethylene glycols, such as monomethoxypolyethylene glycol.
[0040] In a fifth aspect, the present disclosure provides an isolated nucleic acid fragment encoding a variant or fusion protein as described above.
[0041] In a sixth aspect, the present disclosure provides a vector comprising the nucleic acid fragment described above.
[0042] In a seventh aspect, the present disclosure provides a host cell comprising the vector described above.
[0043] In certain embodiments, the host cell is a prokaryotic or eukaryotic cell; the prokaryotic or eukaryotic cell may be selected from E. coli, yeast, insect cells, or mammalian cells, and the mammalian cell may be selected from a CHO cell line or a HEK293 cell line.
[0044] In an eighth aspect, the present disclosure provides a method of preparing the variant or fusion protein described above, the method comprising culturing a host cell as described above and isolating the IL-2 variant or fusion protein expressed by the host cell.
[0045] In a ninth aspect, the present disclosure provides an IL-2 variant or fusion protein prepared by the above method.
[0046] In a tenth aspect, the present disclosure provides a pharmaceutical composition comprising the above variant, fusion protein, conjugate, nucleic acid fragment, vector, or host cell; and a pharma- ceutically acceptable carrier, diluent, or adjuvant; Preferably, the pharmaceutical composition is an injectable pharmaceutical composition, for example, an intravenous or subcutaneous injection; more preferably, the pharmaceutical composition per administration contains an effective amount of the fusion protein administered to a subject; most preferably, the effective amount is from 0.001mpk to 10mpk, for example, 0.001mpk, 0.002mpk, 0.003mpk, 0.004mpk, 0.005mpk, 0.006mpk, 0.007mpk, 0.008mpk, 0.00 9mpk, 0.01mpk, 0.02mpk, 0.03mpk, 0.04mpk, 0.05mpk, 0.06mpk, 0.07mpk, 0.08mpk, 0.09mpk, 0.1mpk, 0.2mpk, 0.3mpk, 0.4mpk, 0.5mpk, 0.6mpk, 0.7mpk, 0.8mpk, 0.9mpk, 1mpk, 2mpk, 3mpk, 4mpk, 5mpk, 6mpk, 7mpk, 8mpk, 9mpk, or 10mpk.
[0047] In an eleventh aspect, the present disclosure provides a use of the variant, fusion protein, conjugate, nucleic acid fragment, vector, or host cell described above in the manufacture of a medicament for the treatment of a disease; Preferably, the medicament is an injectable medicament, e.g., an intravenous or subcutaneous injection; Preferably, each dose of the formulation contains an effective amount of the fusion protein to be administered to the subject; most preferably, the effective amount is from 0.001mpk to 10mpk, e.g., 0.001mpk, 0.002mpk, 0.003mpk, 0.004mpk, 0.005mpk, 0.006mpk, 0.007mpk, 0.008mpk, 0.009mpk, 0.01mpk, 0.02mpk, 0. 0.03mpk, 0.04mpk, 0.05mpk, 0.06mpk, 0.07mpk, 0.08mpk, 0.09mpk, 0.1mpk, 0.2mpk, 0.3mpk, 0.4mpk, 0.5mpk, 0.6mpk, 0.7mpk, 0.8mpk, 0.9mpk, 1mpk, 2mpk, 3mpk, 4mpk, 5mpk, 6mpk, 7mpk, 8mpk, 9mpk, or 10mpk; Preferably, the medicament is used to treat an autoimmune disease, a proliferative disease, or a viral infection; More preferably, the autoimmune disease comprises rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, IgA nephropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, psoriasis, plaque psoriasis, alopecia areata, multiple sclerosis, amyotrophic lateral sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft versus host disease, organ transplant rejection, autoimmune hepatitis, type I diabetes, autoimmune vasculitis, eczema, or asthma; More preferably, the proliferative disease comprises a neoplasm, a solid tumor, a hematological tumor, malignant ascites, or malignant pleural effusion; the solid tumor may be benign or malignant, primary or metastatic, and the malignant solid tumor may be a cancer or sarcoma, such as epithelial cell carcinoma, endothelial cell carcinoma, squamous cell carcinoma, teratoma, lung tumor, papilloma virus-induced cancer, adenocarcinoma, carcinoma, melanoma, hemangiosarcoma, neuroblastoma, metastatic lung cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, Merkel cell carcinoma, ovarian cancer, renal cell carcinoma, metastatic renal cancer, head and neck cancer, bladder cancer, non-muscle invasive bladder cancer, and the like; the hematological tumor may be a leukemia, such as B-cell lymphoma, T-cell lymphoma, cutaneous T-cell lymphoma, T-cell large granular lymphocyte leukemia, lymphoma, multiple myeloma; More preferably, the viral infection is selected from HIV infection, novel coronavirus infection, or HPV viral infection.
[0048] In a twelfth aspect, the present disclosure provides a method of treating an autoimmune disease, a proliferative disease, or a viral infection, the method comprising administering to a subject an effective amount of an IL-2 variant, fusion protein, conjugate, nucleic acid fragment, vector, host cell, or pharmaceutical composition as described above; Preferably, the administering step is performed via injection, e.g., intravenous or subcutaneous injection; Preferably, the effective amount is from 0.001mpk to 10mpk, for example, 0.001mpk, 0.002mpk, 0.003mpk, 0.004mpk, 0.005mpk, 0.006mpk, 0.007mpk, 0.008mpk, 0.009mpk, 0.01mpk, 0.02mpk, 0.03mpk, 0.04mpk, 0.05mpk. , 0.06mpk, 0.07mpk, 0.08mpk, 0.09mpk, 0.1mpk, 0.2mpk, 0.3mpk, 0.4mpk, 0.5mpk, 0.6mpk, 0.7mpk, 0.8mpk, 0.9mpk, 1mpk, 2mpk, 3mpk, 4mpk, 5mpk, 6mpk, 7mpk, 8mpk, 9mpk, or 10mpk; Preferably, the autoimmune disease comprises rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, IgA nephropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, psoriasis, plaque psoriasis, alopecia areata, multiple sclerosis, amyotrophic lateral sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft versus host disease, organ transplant rejection, autoimmune hepatitis, type I diabetes, autoimmune vasculitis, eczema, or asthma; Preferably, the proliferative disease comprises a neoplasm, a solid tumor, a hematological tumor, malignant ascites, or malignant pleural effusion; the solid tumor is optionally selected from benign or malignant, primary or metastatic, and the malignant solid tumor is optionally selected from cancer or sarcoma, such as epithelial cell carcinoma, endothelial cell carcinoma, squamous cell carcinoma, teratoma, lung tumor, papilloma virus-induced cancer, adenocarcinoma, carcinoma, melanoma, hemangiosarcoma, neuroblastoma, metastatic lung cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, Merkel cell carcinoma, ovarian cancer, renal cell carcinoma, metastatic renal cancer, head and neck cancer, bladder cancer, non-muscle invasive bladder cancer; the hematological tumor is optionally selected from leukemia, such as B cell lymphoma, T cell lymphoma, cutaneous T cell lymphoma, T cell large granular lymphocyte leukemia, lymphoma, multiple myeloma; More preferably, the viral infection is selected from HIV infection, novel coronavirus infection, or HPV viral infection.
[0049] In a thirteenth aspect, the present disclosure provides a method of preferentially stimulating regulatory T cells in a T cell population or peripheral blood, the method comprising contacting a T cell population or peripheral blood with an IL-2 variant, fusion protein, conjugate, nucleic acid fragment, vector, host cell, or pharmaceutical composition as described above; Preferably, said preferentially stimulating comprises: (a) preferentially stimulating STAT5 phosphorylation in regulatory T cells over non-regulatory T cells or NK cells; (b) preferentially stimulating the proliferation of regulatory T cells over non-regulatory T cells or NK cells; and / or (c) increasing the ratio of regulatory T cells to non-regulatory T cells, or increasing the ratio of regulatory T cells to NK cells. [Terms and definitions]
[0050] Unless otherwise defined in this disclosure, scientific and technical terms related to this disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art.
[0051] As used herein, the term "IL2" or "IL-2" refers to any native or recombinant IL-2 from any vertebrate, including mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats), as well as domesticated or domesticated mammals, unless otherwise specified. In this disclosure, "IL2" or "IL-2" includes all forms ranging from unprocessed IL-2 (e.g., IL-2 containing a signal peptide at the N-terminus) to mature IL-2 within cells. In this disclosure, "IL2" or "IL-2" also includes natural variants and fragments of IL-2, such as splice variants or allelic variants. In this specification, "IL2" or "IL-2" also includes non-naturally occurring variants, such as IL-2 variants artificially modified by genetic engineering.
[0052] The term "wild-type IL-2" is similar to an IL-2 variant, except that each amino acid at a mutated position in the IL-2 variant remains the wild-type amino acid. For example, if the IL-2 variant is unprocessed IL-2, the wild-type form of the variant is unprocessed IL-2; if the IL-2 variant is mature IL-2, the wild-type form of the variant is mature IL-2; if the IL-2 variant is a truncated form of IL-2, the wild-type form of the variant is the corresponding truncated form of IL-2 having the wild-type sequence. By way of example, "wild-type IL-2" in the present disclosure may have the amino acid sequence as follows: APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITF X QSIISTLT (sequence number 60); in the sequence, the 125th amino acid residue, "X", represents C, S, A, or V.
[0053] As used herein, the term "mutation" includes amino acid substitution, deletion, insertion, or any combination thereof. A "mutation" in this disclosure may be generated by genetic or chemical methods known in the art, including, but not limited to, site-directed mutagenesis, PCR, gene synthesis, and the like.
[0054] Numbering of the "mutation site" of an IL-2 mutant begins with the first amino acid residue (A) of "wild-type IL-2" as shown in SEQ ID NO: 60. As an example, a "Q13 mutation" refers to a mutation of the amino acid residue (Gln, Q) at position 13 of wild-type IL-2 as shown in SEQ ID NO: 60. For example, a "Q13L mutation" refers to an IL-2 mutant in which the amino acid Q (Gln) at position 13 of wild-type IL-2 as shown in SEQ ID NO: 60 has been mutated to L (Leu).
[0055] In the present specification, the punctuation mark " / " used between mutation sites means "and", which indicates that the mutations before and after the " / " coexist simultaneously in the same IL-2 mutant. For example, "Y31 / A73 / H79" means that mutations occur simultaneously in Y31, A73, and H79 of the same IL-2 mutant, and "Y31V / A73L / H79Q" means that Y31V, A73L, and H79Q coexist simultaneously in the same IL-2 mutant.
[0056] As used herein, the term "Tm" (melting temperature) refers to the temperature at which 50% of a protein is denatured. "Tm" in the present disclosure may be determined by any method well known in the art. For example, the Tm value of a protein can be determined by the method shown in Example 3 or Example 6 of the present disclosure.
[0057] The term "fusion protein" in the present disclosure refers to a protein product obtained by joining the coding regions of two or more genes by genetic recombination, chemical, or other suitable methods, and expressing the protein products obtained by genetic recombination under the control of the same regulatory sequence. In the fusion protein of the present disclosure, the coding regions of two or more genes can be fused at one or several points by a sequence encoding linker(s). The linker(s) can be used to construct the fusion protein of the present disclosure.
[0058] As used herein, the term "linker" refers to a peptide used to link IL-2 to another protein molecule or protein fragment to ensure proper folding and stability of the protein, including, but not limited to, Fc. Preferably, the "linker" in the present disclosure is (GGGGS) nWherein n can be 0, 1, 2, 3, 4, or 5. If the linker sequence is too short, it can affect the folding of the higher-order structure of the two proteins, so that the two proteins interfere with each other. If the linker sequence is too long, it can be immunogenic, because the linker sequence itself becomes a new antigen.
[0059] As used herein, the term "second polypeptide" may refer to a single chain polypeptide, such as an scFv antibody. "Second polypeptide" also includes multi-chain polypeptides, where at least one polypeptide chain is fused to IL-2 or a variant thereof, and the other(s) polypeptide chain(s) are linked to the at least one fused polypeptide chain by covalent or non-covalent bonds. For example, in the case of a Fab antibody, the heavy chain of the Fab can be fused to IL-2 or a variant thereof, and the light chain is linked to the heavy chain by a disulfide bond.
[0060] As used herein, the term "Fc" refers to the constant region of an immunoglobulin chain, particularly the C-terminus of the constant region of an immunoglobulin heavy chain or a part thereof. Fc is a region that does not have antigen binding activity and where an antibody interacts with an effector molecule or cell. As used herein, "Fc" may be any Fc or variant thereof derived from a human or non-human mammal. For example, the Fc of an immunoglobulin may comprise a combination of two or more heavy chain domains (CH1, CH2, CH3, or CH4) and an immunoglobulin hinge region. The Fc may be derived from different species, preferably from a human immunoglobulin. According to the amino acid sequence of the heavy chain constant region, immunoglobulins can be divided into different classes, mainly including five immunoglobulin classes: IgA, IgD, IgE, IgG, and IgM. Some of them can be further divided into subclasses (isotypes), such as IgG-1, IgG-2, IgG-3, IgG-4, IgA-1, IgA-2, etc. Preferably, "Fc" includes at least one immunoglobulin hinge region as well as the CH2 and CH3 domains of IgG. More preferably, "Fc" includes the CH2 and CH3 domains of IgG1 and the immunoglobulin hinge region, although the starting amino acid position of the hinge region can vary. Unless otherwise specified, amino acid residues of Fc, constant regions, or antibodies of the present disclosure are numbered according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutions of Health, Bethesda, Md., 1991.
[0061] The term "antibody" in the present disclosure is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antigen-binding fragments, so long as they exhibit the desired antigen-binding activity. Antibodies may include murine antibodies, human antibodies, humanized antibodies, chimeric antibodies, and camelid antibodies. Specifically, an antibody may be an immunoglobulin, which is a tetrapeptide chain structure consisting of two identical heavy chains and two identical light chains linked by interchain disulfide bonds. The constant regions of the immunoglobulin heavy chains differ in terms of amino acid composition and amino acid sequence, and therefore differ in antigenicity. Thus, immunoglobulins can be divided into five classes, or immunoglobulin isotypes, namely IgM, IgD, IgG, IgA, and IgE, and the heavy chains correspond to μ, δ, γ, α, and ε chains, respectively. Ig of the same class can be divided into different subclasses depending on differences in the amino acid composition of the hinge region and differences in the number and positions of disulfide bonds in the heavy chain; for example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains may be divided into κ chains or λ chains depending on differences in the constant region. Each of the five classes of Ig can have a κ chain or a λ chain. In the present disclosure, "antibody" includes scFv, sdFv, Fab, Fab', F(ab') 2 , and Fv.
[0062] As used herein, the term "isolated" refers to removing a material from its original or natural environment (e.g., the environment in which it naturally occurs). Thus, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide is isolated when, through human intervention, it is separated from some or all of the coexisting materials in the natural system.
[0063] An "isolated nucleic acid fragment" is an RNA or DNA polymer that is single- or double-stranded, and optionally contains synthetic, non-natural, or altered nucleotide bases. An isolated nucleic acid fragment in the form of a DNA polymer may consist of one or more cDNA, genomic DNA, or synthetic DNA fragments. A "nucleic acid fragment" of the present disclosure may be part of a vector or may be integrated into a host cell chromosome at a heterologous site. A "nucleic acid fragment" of the present disclosure may be part of a composition. Such a vector or composition is also isolated because it is not part of its natural environment.
[0064] As used herein, the term "vector" includes nucleic acid vectors such as DNA vectors (e.g., plasmids), RNA vectors, viruses, or other suitable replicons (e.g., viral vectors). A variety of vectors have been developed to deliver polynucleotides encoding heterologous proteins to prokaryotic or eukaryotic cells. The "vectors" of the present disclosure may contain additional sequence elements for expressing proteins and / or integrating these polynucleotide sequences into the genome of mammalian cells, control sequences (such as promoter and enhancer regions) for inducing gene transcription, or sequences for increasing the translation rate of genes or improving the stability or nuclear transport of mRNA produced by gene transcription. Sequence elements include, for example, 5' untranslated regions, 3' untranslated regions, internal ribosome entry sites (IRES), and polyadenylation signal sites for efficient transcription of genes on expression vectors. The "vectors" of the present disclosure may further include a polynucleotide encoding a marker for selecting cells containing such a vector. Suitable markers include, for example, genes encoding resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, or nourseothricin.
[0065] As used herein, the term "host cell" refers to a cell into which exogenous nucleic acid has been introduced, and includes the progeny of such a cell. "Progeny" may be identical in nucleic acid content to its parent, or may contain mutations and not be identical to the parent cell. "Progeny" includes mutant progeny that have the same function or biological activity as selected or selected for in the originally transformed cell.
[0066] As used herein, the term "pharmaceutical composition" refers to a mixture containing one or more of the disclosed IL-2 variants, fusion proteins, nucleic acid fragments, vectors, or host cells. The mixture may further contain other components, including, but not limited to, pharma- ceutically acceptable carriers, diluents, or adjuvants. The purpose of the pharmaceutical composition of the present disclosure is to facilitate administration of a drug to an organism, thereby facilitating absorption of the active ingredient to exert its biological activity.
[0067] The term "treatment" in this disclosure refers to surgical or pharmaceutical treatment, the purpose of which is to prevent or alleviate (reduce) the progression of undesirable physiological changes or pathologies, such as cell proliferative disorders (e.g., cancer, or infectious diseases), autoimmune diseases (e.g., systemic lupus erythematosus), in a subject in need of treatment. Beneficial or desired clinical outcomes include, but are not limited to, alleviation of symptoms, inhibition of disease severity, stabilization of disease state (i.e., not worsening), delay or slowing of disease progression, amelioration or alleviation of disease state, and remission (whether partial or complete remission), whether detectable or not. Subjects in need of treatment include those suffering from a disease or disorder, those susceptible to a disease or disorder, or those in whom a disease or disorder is being prevented. The terms "alleviation," "reduction," "mitigation," "amelioration," and "remission," when used, also mean elimination, disappearance, non-occurrence, and the like.
[0068] As used herein, the term "subject" refers to an organism being treated for a particular disease or disorder described herein, such as cancer, an infectious disease, or an autoimmune disease. Subjects and patients include mammals being treated for a disease or disorder, such as, for example, humans, primates, pigs, goats, rabbits, hamsters, cats, dogs, guinea pigs, cows or other bovine animals, sheep, and horses.
[0069] As used herein, the term "effective amount" refers to an amount of a therapeutic agent that is effective in preventing or inhibiting the symptoms or progression of a disease when administered to a cell, tissue, or subject, either alone or in combination with another therapeutic agent. "Effective amount" also refers to an amount of a compound sufficient to alleviate a symptom (e.g., treat, cure, prevent, or alleviate an associated medical condition) or to increase the rate of treating, curing, preventing, or alleviating such a condition. When only one active ingredient is administered to an individual, the therapeutically effective amount refers to that active ingredient alone. When administered together, the therapeutically effective amount refers to the combined amount of the therapeutically active ingredients, whether administered sequentially or simultaneously in combination.
[0070] The term "autoimmune disease" in the present disclosure refers to a disease characterized by cell, tissue, and / or organ damage caused by the subject's own immune response to the cell, tissue, and / or organ.By way of example, autoimmune disease includes, but is not limited to, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, IgA nephropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, psoriasis, plaque psoriasis, alopecia areata, multiple sclerosis, amyotrophic lateral sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft-versus-host disease, organ transplant rejection, autoimmune hepatitis, type I diabetes, autoimmune vasculitis, eczema, or asthma.
[0071] The term "proliferative disorder" of the present disclosure refers to a condition in which the proliferation of cells or tissues is uncontrolled and / or abnormal, which may lead to the development of an undesirable disease or disorder. The tumor may be cancerous or non-cancerous, including but not limited to neoplasms, solid tumors, hematological tumors, malignant ascites, or malignant pleural effusion. The "solid tumor" of the present disclosure may be benign or malignant, primary or metastatic, and the malignant solid tumor may be a carcinoma or sarcoma. By way of example, the "solid tumor" of the present disclosure includes but is not limited to epithelial cell carcinoma, endothelial cell carcinoma, squamous cell carcinoma, teratoma, lung tumor, papilloma virus-induced cancer, adenocarcinoma, carcinoma, melanoma, angiosarcoma, neuroblastoma, metastatic lung cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, Merkel cell carcinoma, ovarian cancer, renal cell carcinoma, metastatic renal cancer, head and neck cancer, bladder cancer, and non-muscle invasive bladder cancer. By way of example, "blood system tumors" of the present disclosure include, but are not limited to, leukemias, such as B cell lymphoma, T cell lymphoma, cutaneous T cell lymphoma, and T cell large granular lymphocyte leukemia, lymphomas, and multiple myeloma.
[0072] As used herein, the term "IL-2 receptor α subunit" (IL-2Rα), also known as "CD25," refers to any naturally occurring IL-2 receptor α subunit or variants thereof from any vertebrate, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). "IL-2 receptor α subunit" includes "full-length" unprocessed IL-2 receptor α subunit, all forms of processed cell-derived IL-2 receptor α subunit, naturally occurring IL-2 receptor α subunit variants (such as splice variants or allelic variants), and variants engineered based on the naturally occurring IL-2 receptor α subunit. In one embodiment, the IL-2 receptor α subunit is a human IL-2 receptor α subunit having an exemplary sequence set forth in SEQ ID NO:57.
[0073] As used herein, the term "IL-2 receptor β subunit" (IL-2Rβ), also known as "CD122," refers to any naturally occurring IL-2 receptor β subunit or variants thereof from any vertebrate, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). IL-2 receptor β subunit includes the "full-length" unprocessed IL-2 receptor β subunit, any form of processed cell-derived IL-2 receptor β subunit, naturally occurring IL-2 receptor β subunit variants (such as splice variants or allelic variants), and artificially engineered variants based on the naturally occurring IL-2 receptor β subunit. In one embodiment, the IL-2 receptor β subunit is a human IL-2 receptor β subunit having an exemplary sequence set forth in SEQ ID NO:58.
[0074] As used herein, the term "IL-2 receptor gamma subunit" (IL-2Rγ), also known as "CD132", refers to any naturally occurring IL-2 receptor gamma subunit or variants thereof from any vertebrate, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). IL-2 receptor gamma subunit includes "full-length" unprocessed IL-2 receptor gamma subunit, any form of processed cell-derived IL-2 receptor gamma subunit, naturally occurring IL-2 receptor gamma subunit variants (such as splice variants or allelic variants), and variants engineered based on the naturally occurring IL-2 receptor gamma subunit. In one embodiment, the IL-2 receptor gamma subunit is a human IL-2 receptor gamma subunit having an exemplary sequence set forth in SEQ ID NO:59.
[0075] As used herein, the term "regulatory T cells" or "T 制御性細胞 The term "Treg," also known as "Treg," refers to specialized CD4 T cells that can inhibit the responses of other T cells. +A type of T cell. Tregs are characterized by the expression of the IL-2 receptor α subunit (CD25) and the transcription factor forkhead box protein P3 (FOXP3), and play an important role in inducing and maintaining peripheral self-tolerance to antigens. Tregs require IL-2 to exert their functions and to express and induce inhibitory properties.
[0076] As used herein, the term "binding ability" refers to a bond or interaction exerted between a pair of molecules. Typical pairing molecules include a ligand and a receptor, an antigen and an antibody, an enzyme and a substrate, and more specifically, for example, IL2 and an IL-2Rβγ subunit complex, or IL-2 and an IL-2Rαβγ subunit complex. The "binding ability" of the present disclosure can be detected by a conventional method in the art, including, but not limited to, ELISA or FACS. [Brief description of the drawings]
[0077] [Figure 1] Figure 1 shows the expression level of human IL-2 receptor α protein in CHO-K1 hIL-2-Rα recombinant cell line (clone 1A6) detected by flow cytometry (FACS), the antibody against IL-2 receptor α was purchased from BioLegend, and the negative control refers to the isotype control. [Diagram 2] Figure 2 shows the expression level of human IL-2 receptor β protein in CHO-K1 hIL-2Rβ recombinant cell line (clone 2A5) detected by flow cytometry (FACS), the antibody against IL-2 receptor β was purchased from BioLegend, and the negative control refers to the isotype control. [Diagram 3]Figure 3 shows the expression level of human IL-2 receptor βγ protein in CHO-K1 hIL-2Rβγ recombinant cell line (clone 2E6) detected by flow cytometry (FACS), the antibodies against IL-2 receptor β and IL-2 receptor γ, respectively, were purchased from BioLegend, and the negative control is an isotype control. Figure 3A shows the expression level of human IL-2 receptor β protein. Figure 3B shows the expression level of human IL-2 receptor γ protein. [Figure 4] Figure 4 shows the expression level of human IL-2 receptor αβγ protein in CHO-K1 hIL-2Rαβγ recombinant cell line (clone 2D6) detected by flow cytometry (FACS), where antibodies against IL-2 receptor α, IL-2 receptor β, and IL-2 receptor γ were purchased from BioLegend, and the negative control refers to the expression level of the corresponding receptor in parental CHO-K1 cells. Figure 4A shows the expression level of human IL-2 receptor α protein. Figure 4B shows the expression level of human IL-2 receptor β protein. Figure 4C shows the expression level of human IL-2 receptor γ protein. [Diagram 5]Figure 5 shows the binding activity of IL-2 mutant proteins to CHO-K1 IL-2 receptor αβγ recombinant cells and IL-2 receptor βγ recombinant cells detected by flow cytometry (FACS). Figure 5A shows the binding activity of mut7.36-linker2-hFc, mut11.08-linker2-hFc, mut61-linker2-hFc, mut61.08-linker2-hFc, or mut61.46-linker2-hFc to CHO-K1 IL-2 receptor αβγ recombinant cells. Figure 5B shows the binding activity of mut11.31-linker2-hFc or mut7.66-linker2-hFc to CHO-K1 IL-2 receptor αβγ recombinant cells. Figure 5C shows the binding activity of mut7.36-linker2-hFc, mut11.08-linker2-hFc, mut61-linker2-hFc, mut61.08-linker2-hFc, or mut61.46-linker2-hFc to CHO-K1 IL-2 receptor βγ recombinant cells. Figure 5D shows the binding activity of mut11.31-linker2-hFc or mut7.66-linker2-hFc to CHO-K1 IL-2 receptor βγ recombinant cells. [Figure 6]FIG. 6 shows the effect of IL-2 mutant proteins on STAT5 phosphorylation levels in Tregs (FIG. 6A to FIG. 6C), CD4+CD25-FoxP3-T cells (FIG. 6D to FIG. 6F), and CD8+T cells (FIG. 6G to FIG. 6I). FIG. 6A shows the effect of mut7.36-linker2-hFc on STAT5 phosphorylation levels in Tregs. FIG. 6B shows the effect of mut11.08-linker2-hFc on STAT5 phosphorylation levels in Tregs. FIG. 6C shows the effect of mut11.31-linker2-hFc or mut7.66-linker2-hFc on STAT5 phosphorylation levels in Tregs. FIG. 6D shows the effect of mut7.36-linker2-hFc on phosphorylation levels in CD4+CD25-FoxP3-T cells. Figure 6E shows the effect of mut11.08-linker2-hFc on phosphorylation levels in CD4+CD25-FoxP3-T cells. Figure 6F shows the effect of mut11.31-linker2-hFc or mut7.66-linker2-hFc on phosphorylation levels in CD4+CD25-FoxP3-T cells. Figure 6G shows the effect of mut7.36-linker2-hFc on phosphorylation levels in CD8+T cells. Figure 6H shows the effect of mut11.08-linker2-hFc on phosphorylation levels in CD8+T cells. Figure 6I shows the effect of mut11.31-linker2-hFc or mut7.66-linker2-hFc on phosphorylation levels in CD8+T cells. [Figure 7]FIG. 7 shows the effect of IL-2 mutant proteins on the proliferation levels of Tregs (FIG. 7A and FIG. 7B), CD4+CD25-FoxP3-T cells (FIG. 7C and FIG. 7D), and CD8+CD25-T cells (FIG. 7E and FIG. 7F). FIG. 7A shows the effect of mut7.36-linker2-hFc or mut7.66-linker2-hFc on the proliferation levels of Tregs. FIG. 7B shows the effect of mut11.08-linker2-hFc or mut11.31-linker2-hFc on the proliferation levels of Tregs. FIG. 7C shows the effect of mut7.36-linker2-hFc or mut7.66-linker2-hFc on the proliferation levels of CD4+CD25-FoxP3-T cells. Figure 7D shows the effect of mut11.08-linker2-hFc or mut11.31-linker2-hFc on the proliferation level of CD4+CD25-FoxP3-T cells. Figure 7E shows the effect of mut7.36-linker2-hFc or mut7.66-linker2-hFc on the proliferation level of CD8+CD25-T cells. Figure 7F shows the effect of mut11.08-linker2-hFc or mut11.31-linker2-hFc on the proliferation level of CD8+CD25-T cells. [Figure 8] FIG. 8 shows the effect of IL-2 mutant proteins on the proliferation levels of NK cells. [Figure 9A] FIG. 9A shows the percentage of Tregs among splenic CD4+ T cells. [Figure 9B] FIG. 9B shows the percentage of CD4+CD25-Foxop3- cells among splenic CD4+ cells. [Figure 9C] FIG. 9C shows the percentage of CD3+CD4- cells among splenic CD3+ cells. [Figure 10A] FIG. 10A shows the percentage of Tregs in peripheral blood CD4+ cells. [Figure 10B] FIG. 10B shows the percentage of CD4+CD25-Foxop3- cells among peripheral blood CD4+ cells. [Figure 10C] FIG. 10C shows the percentage of CD3+CD4- cells among peripheral blood CD3+ cells. [Figure 11A] FIG. 11A shows the change in Δ ear thickness in different groups of wild-type mouse DTH model, where Δ ear thickness refers to the change in thickness of the right ear before and after stimulation. [Figure 11B] FIG. 11B shows the changes in body weight in different groups of wild-type mouse DTH model. [Figure 12A] FIG. 12A shows the change in Δ ear thickness in different groups of wild-type mouse DTH model, where Δ ear thickness refers to the change in thickness of the right ear before and after stimulation. [Figure 12B] FIG. 12B shows the changes in body weight in different groups of wild-type mouse DTH model. [Figure 13A] FIG. 13A shows Treg / Tcon in different groups of NOG mice. [Figure 13B] FIG. 13B shows Treg / CD8+ in different groups of NOG mice. [Figure 14A] FIG. 14A shows the number of Tregs in different groups of NOG mice. [Figure 14B] FIG. 14B shows the numbers of Tcon in different groups of NOG mice. [Figure 14C] FIG. 14C shows the number of CD8+ cells in different groups of NOG mice. [Figure 15A] FIG. 15A shows the changes in body weight in different groups of NOG mice. [Figure 15B] FIG. 15B shows the GVHD scores in different groups of NOG mice. [Figure 16A] FIG. 16A shows plasma drug concentrations in wild-type mice after subcutaneous administration. [Figure 16B] FIG. 16B shows plasma drug concentrations in wild-type mice after subcutaneous administration. [Figure 17] FIG. 17 shows plasma drug concentrations in wild-type mice after intravenous administration. [Figure 18] FIG. 18 shows plasma drug concentrations in PBMC-inoculated mice following subcutaneous administration. [Figure 19] FIG. 19 shows plasma drug concentrations in cynomolgus monkeys after subcutaneous administration. [Figure 20A] FIG. 20A shows the number of Tregs in cynomolgus monkeys after subcutaneous administration. [Figure 20B] FIG. 20B shows the fold change in Treg numbers in cynomolgus monkeys after subcutaneous administration. [Figure 20C] FIG. 20C shows the percentage of Tregs among CD4+ T cells in cynomolgus monkeys after subcutaneous administration. [Figure 20D] FIG. 20D shows the percentage of Ki67+ Tregs in cynomolgus monkeys after subcutaneous administration. [Figure 20E] FIG. 20E shows the fold change in mean fluorescence intensity of FoxP3 in cynomolgus monkeys after subcutaneous administration. [Figure 20F] FIG. 20F shows the fold change in mean fluorescence intensity of CD25 in cynomolgus monkeys after subcutaneous administration. [Figure 21A] FIG. 21A shows the number of FoxP3− CD4+ cells in cynomolgus monkeys after subcutaneous administration. [Figure 21B] FIG. 21B shows the fold change in FoxP3− CD4+ cell numbers in cynomolgus monkeys after subcutaneous administration. [Figure 21C] FIG. 21C shows the number of CD8+ T cells in cynomolgus monkeys after subcutaneous administration. [Figure 21D] FIG. 21D shows the fold change in CD8+ T cell numbers in cynomolgus monkeys after subcutaneous administration. [Figure 21E] FIG. 21E shows the number of NK cells in cynomolgus monkeys after subcutaneous administration. [Figure 21F] FIG. 21F shows the fold change in NK cell numbers in cynomolgus monkeys after subcutaneous administration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0078] The present disclosure will be further described below with reference to specific examples. The advantages and features of the present disclosure will become apparent from this description. If no specific conditions are given in the examples, the conventional conditions or conditions suggested by the manufacturer shall be followed. If no manufacturer is given, the reagents and equipment used are commercially available conventional products.
[0079] The following examples of the present disclosure are merely illustrative and are not intended to limit the scope of the present disclosure. Those skilled in the art should understand that the details and forms of the technical solutions of the present disclosure can be modified or substituted without departing from or exceeding the spirit or scope of the present disclosure, and all such modifications and substitutions are within the scope of protection of the present disclosure.
[0080] Example 1 - Design of IL-2 mutants with improved thermostability and construction of expression plasmids
[0081] In order to obtain IL-2 mutants with improved thermostability, the corresponding sequences were designed and synthesized using various algorithms. After cloning the nucleic acid fragments encoding wild-type IL-2 and the above-mentioned IL-2 mutants into a pTT5 vector with an Fc tag, the plasmids encoding the following fusion proteins were prepared by standard methods established in molecular biology: IL-2-linker2-hFc, mut0.08-linker2-hFc, mut0.31-linker2-hFc, mut0.36-linker2-hFc, mut0.39-linker2-hFc, mut0.46-linker2-hFc, mut0.57-linker2-hFc, mut0.66-linker2-hFc, and mut0.68-linker2-hFc.
[0082] Specific sequences of the above fusion proteins and components are shown in Table 1. In the table, "IL-2" represents wild-type IL-2, and "mutXX" represents an IL-2 mutant that has a mutation compared to wild-type IL-2.
[0083] Table 1. Sequences of IL-2 mutants with improved stability
[0084] [Table 1-1]
[0085] [Table 1-2]
[0086] [Table 1-3]
[0087] Example 2 - Production and purification of IL-2 variants with improved thermostability
[0088] HEK293 cells (purchased from the Cell Bank of the Chinese Academy of Sciences) were transiently transfected (PEI, Polysciences) with the plasmid constructed in Example 1, and then grown in FreeStyle® 293 Expression Medium (purchased from Gibco) at 37° C. After 7 days, the cell culture medium was collected and the cellular components were removed by centrifugation to obtain a culture supernatant containing the IL-2-hFc fusion protein.
[0089] The fusion protein in the cell culture supernatant was purified using a 10 mL Protein A column (purchased from BestChrom). First, the Protein A column was equilibrated with 3 to 5 column volumes of equilibration buffer (PBS phosphate buffer, pH 7.4), and then the clear culture supernatant was loaded at a flow rate of 10 mL / min. After loading, the Protein A column was washed with 3 to 5 column volumes of equilibration buffer. The proteins bound to the Protein A column were eluted with elution buffer (0.02 M citrate buffer, 0.1 M glycine, 0.1 M sodium chloride, pH 3.0), and the elution was monitored with a nucleic acid / protein detector (A280 ultraviolet absorption peak). The eluted proteins were collected and neutralized by adding a buffer (1 M arginine, 0.4 M succinic acid, pH 9.0). The target protein was then collected by passing it through a molecular sieve (purchased from Bestchrom) using a buffer system (20 mM PB, 200 mM sodium chloride, pH 6.0 to pH 6.5). The purified IL-2 mutant fusion protein was obtained by sterile filtration through a 0.22 μm filter and stored under sterile conditions.
[0090] Purified IL-2 mutant fusion proteins were tested and analyzed for protein yield, concentration (A280 / 1.4), and SEC purity. Purified IL-2 mutant fusion proteins (mutXX-linker2-hFc) with improved thermal stability were identified. These had significantly higher yields compared to wild-type IL-2 (IL2-linker2-hFc). Protein yield, concentration, and purity results are shown in Table 2.
[0091] Table 2. Detection results of IL-2 mutant fusion proteins with improved thermal stability
[0092] [Table 2]
[0093] Example 3 - Differential Scanning Fluorometry (DSF) Assay of IL-2 Mutants with Improved Thermostability
[0094] 50-fold diluted Protein Thermal Shift Dye Kit (purchased from Applied Biosystems, Cat. No. 4461146) buffer, 0.5 mg / mL diluted IL-2 mutant protein (purified as described in Example 2), and 2-fold diluted dye were added to 20 μL of reaction. After mixing to homogeneity, the mixture was added to 8-tube strips in duplicate for each sample. The tubes were capped, centrifuged for 5-10 seconds, and analyzed on an Applied Biosystems 7500. The melting curves were then analyzed using the Boltzmann method to obtain Tm values. As shown in Table 3, compared to wild-type IL-2 (IL2-linker2-hFc), the IL-2 mutants (mutXX-linker2-hFc) had a Tm value increased by more than 3°C, thereby significantly improving thermal stability.
[0095] Table 3. DSF assay results for IL-2 mutants with improved thermostability
[0096] [Table 3]
[0097] Example 4 - Design of IL-2 mutants (IL-2 mutants with reduced binding to the βγ subunit and IL-2 mutants with reduced binding to the βγ subunit and improved thermostability) and construction of expression plasmids
[0098] Using various algorithms including MOE software, the interaction between human IL-2 and the corresponding receptor α subunit, receptor β subunit, and receptor γ subunit was simulated to obtain mutation sites with reduced binding ability to the βγ subunit. IL-2 mutant sequences with mutation sites with reduced binding activity to the βγ subunit were designed and synthesized, as well as IL-2 mutant sequences with combinations of such mutation sites and mutation sites with improved thermal stability. Nucleic acid fragments encoding wild-type IL-2 and the above IL-2 mutants were cloned into a pTT5 vector with an Fc tag, and then plasmids encoding the following fusion proteins were prepared according to standard methods established in molecular biology: IL-2-linker2-hFc, mut7-linker2-hFc, mut7.08-linker2-hFc, mut7.36-linker2-hFc, mut7.39-linker2-hFc, mut7.46-linker2-hFc, mut7.57-linker2-hFc, mut7.60-linker2-hFc, mut7.70-linker2-hFc, mut7.80-linker2-hFc, mut7.90-linker2-hFc, mut7.10-linker2-hFc, mut7.12-linker2-hFc, mut7.16-linker2-hFc, mut7.18-linker2-hFc, mut7.19-linker2-hFc, mut7.20-linker2-hFc, mut7.23-linker2-hFc, mut7.24-linker2-hFc, mut7.25-linker2-hFc, mut7.26-linker2-hFc, mut7.27-linker2-hFc, mut7.28-linker2-hFc, mut7.2 2-hFc, mut7.66-linker2-hFc, mut8-linker2-hFc, mut8.08-linker2-hFc, mut8.36-linker2-hFc, mut11-linker2-hFc, mut11.08-linker2-hFc, mut11.31-linker2-hFc, mut11.36-linker2-hFc, mut11.46-linker2-hFc, mut61-linker2-hFc, mut61.08-linker2-hFc, and mut61.46-linker2-hFc. Specific sequences of the fusion proteins and their components are shown in Table 4. In the table, "IL-2" represents wild-type IL-2, and "mutXX" represents IL-2 mutants that have been mutated compared to wild-type IL-2.
[0099] Table 4. Sequences of IL-2 mutants
[0100] [Table 4-1]
[0101] [Table 4-2]
[0102] [Table 4-3]
[0103] [Table 4-4]
[0104] [Table 4-5]
[0105] [Table 4-6]
[0106] Example 5 - Production and purification of IL-2 variants
[0107] The plasmid constructed in Example 4 was used to transiently transfect HEK293 cells (purchased from the Cell Bank of the Chinese Academy of Sciences) (PEI, Polysciences), and then the cells were grown in FreeStyle® 293 Expression Medium (purchased from Gibco) at 37° C. After 7 days, the cell culture medium was collected, and the cellular components were removed by centrifugation to obtain a culture supernatant containing the IL-2-hFc fusion protein.
[0108] The fusion protein in the cell culture supernatant was purified using a 10 mL Protein A column (purchased from BestChrom). First, the Protein A column was equilibrated with 3 to 5 column volumes of equilibration buffer (PBS phosphate buffer, pH 7.4), and then the clear culture supernatant was loaded at a flow rate of 10 mL / min. After loading, the Protein A column was washed with 3 to 5 column volumes of equilibration buffer. The proteins bound to the Protein A column were eluted with elution buffer (0.02 M citrate buffer, 0.1 M glycine, 0.1 M sodium chloride, pH 3.0), and the elution was monitored with a nucleic acid / protein detector (A280 ultraviolet absorption peak). The eluted proteins were collected and neutralized by adding a buffer (1 M arginine, 0.4 M succinic acid, pH 9.0). The target protein was then collected by passing it through a molecular sieve (purchased from Bestchrom) using a buffer system (20 mM PB, 200 mM sodium chloride, pH 6.0 to pH 6.5). The purified IL-2 mutant fusion protein was obtained by sterile filtration through a 0.22 μm filter and stored under sterile conditions.
[0109] The purified IL-2 mutant fusion protein (mutXX-linker2-hFc) was analyzed for protein concentration (A280 / 1.4) and SEC purity. The purified IL-2 mutant fusion protein was identified. The results of protein purity and concentration are shown in Table 5.
[0110] Table 5. Detection results of IL-2 mutant fusion proteins
[0111] [Table 5]
[0112] Example 6 DSF Assay of IL-2 Mutants
[0113] 50-fold diluted Protein Thermal Shift Dye Kit (purchased from Applied Biosystems, Catalog No. 4461146) buffer, 0.5 mg / mL diluted IL-2 mutant protein (purified in Example 5), and 2-fold diluted dye were added to 20 μL of reaction system. After uniform mixing, the mixture was added to 8-tube strips in duplicate for each sample. The tubes were capped, centrifuged for 5 to 10 seconds, and analyzed on an Applied Biosystems 7500. The melting curves were then analyzed using the Boltzmann method to obtain the Tm values. The specific Tm values are shown in Table 6.
[0114] According to the results shown in Table 6, compared with wild-type IL-2 (IL2-linker2-hFc), the IL-2 mutants (mutXX-linker2-hFc) of Examples 4 and 5 had Tm values increased by more than 5° C., and some IL-2 mutants had Tm values increased by more than 9° C. As described above, the thermal stability was significantly improved in all mutants.
[0115] Surprisingly, IL-2 mutants with reduced βγ-subunit binding had increased Tm values and improved thermostability compared to wild-type IL-2. Mutants with additional combinations of thermostable mutations maintained high Tm values, and some of these combinations had Tm values increased by more than 2°C, up to 6°C, compared to IL-2 mutants with only βγ-subunit-reducing mutations, further improving thermostability.
[0116] Table 6. Results of DSF assay of IL-2 mutants
[0117] [Table 6]
[0118] Example 7 - Construction of stably transfected cell lines overexpressing the human IL-2 receptor or the mouse IL-2 receptor
[0119] A. Construction of a stably transfected cell line overexpressing human IL-2 receptor alpha
[0120] The amino acid sequence of human IL-2 receptor α subunit (gene registration number in NCBI is P01589, specific sequence is as shown in SEQ ID NO: 57) was cloned into pLVX-IRES-Puro vector for lentivirus packaging (purchased from Eubio, catalog number VT1464). Then, CHO-K1 cell line (purchased from Cell Bank of Chinese Academy of Sciences) was transfected with the lentivirus. After 72 hours of transfection with the virus, CHO cells were detected by flow cytometry using a known IL-2 receptor α subunit antibody (product number 302606, purchased from BioLegend). When it was detected that the transfected cells had started to express human IL-2 receptor α subunit, puromycin (purchased from Gibco) was added for screening. After the cells were harvested, they were subcloned into 96-well culture plates by limiting dilution and incubated at 37°C, 5% (v / v) CO 2 The cells were cultured at 100° C. for about 2 weeks. After about 2 weeks, some monoclonal cells were selected and expanded into 6-well plates. The expanded clones were further screened by flow cytometry using a known IL-2 receptor α subunit antibody. Monoclonal cell lines with better growth and higher fluorescence intensity were selected for further expansion, re-detected by flow cytometry, and then frozen in liquid nitrogen to obtain stably transfected cell lines expressing human IL-2 receptor α subunit. The specific selection results are shown in Table 7 and Figure 1. The positive cells (%) in Table 7 refer to the percentage of positive cells in the total number of cells. Table 7 shows that a series of CHO-K1 cell lines overexpressing IL-2 receptor α subunit were prepared.
[0121] Table 7. FACS characterization of CHO-K1 cells expressing human IL-2 receptor alpha
[0122] [Table 7]
[0123] B. Construction of a stably transfected cell line overexpressing human IL-2 receptor β
[0124] The amino acid sequence of human IL-2 receptor β subunit (gene registration number in NCBI is P14784, specific sequence is as shown in SEQ ID NO: 58) was cloned into pLVX-IRES-Puro vector for lentivirus packaging (purchased from Eubio, catalog number VT1464). Then, CHO-K1 cell line (purchased from Cell Bank of Chinese Academy of Sciences) was transfected with the lentivirus. After 72 hours of transfection with the virus, CHO-K1 cells were detected by flow cytometry using a known IL-2 receptor β subunit antibody (catalog number 339010, purchased from BioLegend). When it was detected that the transfected cells had started to express human IL-2 receptor β subunit, puromycin (purchased from Gibco) was added for screening. After the cells were harvested, they were subcloned into 96-well culture plates by limiting dilution and incubated at 37°C, 5% (v / v) CO 2 The cells were cultured at 100° C. for about 2 weeks. After about 2 weeks, some monoclonal cells were selected and expanded into 6-well plates. The expanded clones were further screened by flow cytometry using a known IL-2 receptor β subunit antibody. Monoclonal cell lines with better growth and higher fluorescence intensity were selected for further expansion, re-detected by flow cytometry, and then frozen in liquid nitrogen to obtain stably transfected cell lines expressing human IL-2 receptor β subunit. The specific selection results are shown in Table 8 and FIG. 2. The positive cells (%) in Table 8 refer to the percentage of positive cells in the total number of cells. Table 8 shows that a series of CHO-K1 cell lines overexpressing IL-2 receptor β subunit were prepared.
[0125] Table 8. FACS characterization of CHO-K1 cells expressing human IL-2 receptor β
[0126] [Table 8]
[0127] C. Construction of a stably transfected cell line overexpressing the human IL-2 receptor βγ
[0128] The amino acid sequence of human IL-2 receptor gamma subunit (gene accession number in NCBI is P31785, specific sequence is as shown in SEQ ID NO: 59) was cloned into pLVX-IRES-Hygro vector for lentivirus packaging. Then, CHO-K1 cell line overexpressing human IL-2 receptor beta subunit (CHO-K1 hIL-2Rβ, clone 2A5) was transfected with lentivirus. After 72 hours of transfection with virus, CHO-K1 cells were detected by flow cytometry using known IL-2 receptor beta subunit and IL-2 receptor gamma subunit antibodies (catalog numbers 339010 and 338608, purchased from BioLegend). When it was detected that the transfected cells had started to express human IL-2 receptor beta gamma subunit, puromycin and hygromycin (purchased from Gibco and Thermo) were added for screening. Cells were harvested and then subcloned into 96-well culture plates by limiting dilution and incubated at 37°C, 5% (v / v) CO 2The cells were cultured at 100° C. for about 2 weeks, and some monoclonal cells were selected and expanded into 6-well plates. The expanded clones were further screened by flow cytometry using known IL-2 receptor β subunit and IL-2 receptor γ subunit antibodies. Monoclonal cell lines with better growth and higher fluorescence intensity were selected for further expansion, re-detected by flow cytometry, and then frozen in liquid nitrogen to obtain stably transfected cell lines expressing human IL-2 receptor βγ subunit. The specific selection results are shown in Table 9 and Figures 3A and 3B. The positive cells (%) in Table 9 refer to the percentage of positive cells in the total number of cells. Table 9 shows that a series of CHO-K1 cell lines overexpressing IL-2 receptor βγ subunit were prepared.
[0129] Table 9. FACS characterization of CHO-K1 cells expressing human IL-2 receptor βγ
[0130] [Table 9]
[0131] D. Construction of a stably transfected cell line overexpressing the human IL-2 receptor αβγ
[0132] The amino acid sequence of human IL-2 receptor α subunit was cloned into pLVX-IRES-zsGreen vector for lentivirus packaging. CHO-K1 cell line overexpressing human IL-2 receptor βγ subunit was transfected with bench virus. After 72 hours of transfection with virus, CHO-K1 cells were detected by flow cytometry using known IL-2 receptor α subunit antibody, IL-2 receptor β subunit antibody, and IL-2 receptor γ subunit antibody (ibid., purchased from BioLegend). When it was detected that the transfected cells had started to express human IL-2 receptor αβγ subunit, puromycin and hygromycin (purchased from Gibco and Thermo) and GFP (for fluorescence expression) were added for screening. After the cells were harvested, they were subcloned into 96-well culture plates by limiting dilution and incubated at 37°C, 5% (v / v) CO 2 The cells were cultured at 100° C. for about 2 weeks, and some monoclonal cells were selected and expanded into 6-well plates. The expanded clones were further screened by flow cytometry using known IL-2 receptor α subunit, IL-2 receptor β subunit, and IL-2 receptor γ subunit antibodies. Monoclonal cell lines with better growth and higher fluorescence intensity were selected for further expansion, re-detected by flow cytometry, and then frozen in liquid nitrogen to obtain stably transfected cell lines expressing human IL-2 receptor αβγ subunit. Specific selection results are shown in Table 10 and Figures 4A and 4B. The positive cells (%) in Table 10 refer to the percentage of positive cells in the total number of cells. Table 10 shows that a series of CHO-K1 cell lines overexpressing IL-2 receptor αβγ subunit were prepared.
[0133] Table 10. FACS characterization of CHO-K1 cells expressing human IL-2 receptor αβγ
[0134] [Table 10]
[0135] Table 11. Sequence information of genes used in the construction of stably transfected cell lines in Example 7 (A to D) and the proteins they encode.
[0136] [Table 11]
[0137] Example 8 - Detection of binding activity of IL-2 mutants to receptor-expressing cells by flow cytometry (FACS)
[0138] CHO-K1 cells expressing IL-2 receptor αβγ (CHO-K1 hIL-2Rαβγ 2D6) or IL-2 receptor βγ (CHO-K1 hIL-2Rβγ 2E6) were grown in T-75 cell culture flasks to 90% confluence. After removing the medium, the flasks were washed once with PBS buffer (purchased from Hyclone, catalog number SH30256.01). The cells were treated with 2 mL of trypsin (purchased from Invitrogen, catalog number 25200072) containing 0.25% EDTA for 2 to 3 minutes, neutralized with 8 mL of DMEM / F-12 (purchased from Gibco, catalog number 12634-010) containing 10% (w / w) fetal bovine serum (purchased from Gibco, catalog number 10099-141C), pipetted 3 to 4 times, then collected in a 15 ml centrifuge tube, counted, and centrifuged at 1000 rpm for 5 minutes at room temperature. After discarding the culture medium, the cells were resuspended in RPMI-1640 (purchased from Gibco, catalog number A10491-01) containing 2% (w / w) fetal bovine serum, and then diluted to 1.43 × 10 6The IL-2 mutants were diluted to 1000 cells / ml. The cells were added to a U-bottom 96-well FACS reaction plate at 70 μL per well and placed on 4°C or ice for later use. The IL-2 mutants to be detected were diluted in RPMI-1640 containing 2% (w / w) fetal bovine serum, added to the cells at 30 μL per well, mixed well, and incubated on ice for 1 hour. The plate was then washed twice with FACS buffer (PBS buffer containing 2% (w / w) bovine serum albumin). Fluorescently labeled secondary antibodies (purchased from BioLegend, catalog number 409306) were added to the plate at 100 μL per well and incubated on ice for 30 minutes. The plate was then washed twice with FACS buffer. Detection and analysis were performed by FACS (FACS Canto II, purchased from BD Company). Alternatively, cells were suspended in 100 μL of FACS buffer containing 2% (w / w) paraformaldehyde (purchased from Dingguo, Catalog No. AR-0211), and then stored at 4° C. until further FACS detection. 100 μL of PBS buffer was added to each well before FACS detection. FACS detection and analysis were performed. The results are shown in Figure 5A to Figure 5D and Table 12 and Table 13. The results show that the IL-2 mutants were able to bind to human IL-2 receptor αβγ trimers on the cell surface. The binding activity of the IL-2 mutants to human IL-2 receptor βγ dimers on the cell surface was weaker than that of wild-type IL-2. The binding activity of mut61-linker2-hFc, mut61.08-linker2-hFc, and mut61.46-linker2-hFc to CHO-K1 IL-2Rβγ dimer was greatly inhibited. In the table below, MFI is the mean fluorescence intensity of the detected cell population.
[0139] Table 12. Binding activity of IL-2 mutants to CHO-K1 IL2 receptor αβγ recombinant cell line (CHO-K1 IL2Rαβγ) detected by FACS.
[0140] [Table 12]
[0141] Table 13. Binding activity of IL-2 mutants to the CHO-K1 IL2 receptor βγ recombinant cell line (CHO-K1 IL2Rβγ) detected by FACS.
[0142] [Table 13]
[0143] Example 9 - Activation of signaling pathways by IL-2 in different cells detected by STAT5 phosphorylation assay
[0144] Frozen peripheral blood mononuclear cells (PBMCs) (purchased from All Cells) were thawed. 5 × 10 5 50 μL of PBMCs and 50 μL of IL-2 mutants were added to each well and reacted for 15 minutes in a carbon dioxide incubator. After the reaction, 100 μL of pre-chilled DPBS was added to each well to stop the reaction. After centrifugation, PBMCs were stained with Live Dead Violet (Invitrogen-L34964), fixed with FixI (BD-557870) for 10 minutes at 37°C, and permeabilized with PermIII (BD-558050) for 30 minutes on ice. PBMCs were then stained with CD3-AF700 (BD-557943), CD4-PerCP Cy5.5 (BD-560650), CD8-FTIC (BD-555366), CD25-PE (BD-557138), FoxP3-AF647 (BD-560045), and pSTAT5-PE Cy7 (Invitrogen-25-9010-42) for 1 hour at room temperature and washed twice before detection. Results are shown in Figures 6A to 6I and Tables 14 to 16. Results show that the levels of STAT5 phosphorylation activated by IL-2 mutants were similar in Treg cells compared to wild type IL-2, but not in CD4 + CD25 - FoxP3 - T cells or CD8 +The results show that STAT5 phosphorylation was significantly decreased in T cells. In the table below, MFI is the mean fluorescence intensity of STAT5 phosphorylation in the detected cell population.
[0145] Table 14. STAT5 phosphorylation signals activated by IL-2 mutants in Tregs detected by FACS
[0146] [Table 14]
[0147] Table 15. CD4 detected by FACS + CD25 - FoxP3 - STAT5 phosphorylation signal activated by IL-2 mutants in T cells
[0148] [Table 15]
[0149] Table 16. CD8 detected by FACS + STAT5 phosphorylation signal activated by IL-2 mutants in T cells
[0150] [Table 16]
[0151] Example 10 - Modulatory effect of IL-2 mutants on T cell proliferation
[0152] Frozen PBMCs were thawed, resuspended in RPMI-1640 (purchased from Gibco, catalog number A10491-01) containing 10% FBS (purchased from Gibco, catalog number 10099-141C), and cultured for 2 days in 6-well plates precoated with 100 ng / ml CD3 antibody (purchased from BD, catalog number 566685). Cells were harvested, washed three times with PBS buffer (purchased from Hyclone, catalog number SH30256.01), resuspended in RPMI-1640 containing 10% FBS, and cultured for 5 days in 6-well plates. The cells were then harvested, washed once with PBS buffer, stained with cell trace violet (purchased from Invitrogen, catalog number C34557), washed once with culture medium, resuspended in culture medium, added to a 24-well plate (900 μL cells per well), added with 100 μL of IL-2 mutant protein sample, and cultured for 7 days. The cells were then harvested, resuspended in PBS (purchased from Sangon Biotech, catalog number B548117-0500) containing 1% BSA (purchased from Sangon Biotech, catalog number A500023-0100), and added to a 96-well plate.
[0153] Cells were stained with BV605-CD8 (purchased from BioLegend, catalog number 344742) for 30 minutes at room temperature, washed with PBS containing 1% BSA, fixed with 200 μL per well of Fixative (purchased from eBioscience, catalog number 00-5523-00) for 30 minutes at 4° C., washed with PBS containing 1% BSA, and then permeabilized with 200 μL per well of Permeabilization Solution (purchased from eBioscience, catalog number 00-5523-00) for 30 minutes at 4° C. and washed with PBS containing 1% BSA. The cells were further stained with APC-CY7-CD3 antibody (purchased from BioLegend, Catalog No. 344818), CD25 antibody (purchased from BioLegend, Catalog No. 302606), and Foxp3 antibody (purchased from Thermo Fisher, #17-4777-42) for 30 min at room temperature, washed with PBS containing 1% BSA, resuspended in 200 μL PBS containing 1% BSA, and detected and analyzed by FACS (FACS Canto II, purchased from BD). The results are shown in Figures 7A to 7F and Tables 17 to 19. The results show that the effect of IL-2 mutants on Treg proliferation is similar compared to wild-type IL-2, but the CD4 + CD25 - FoxP3 - T cells or CD8 + T CD25 - For T cells, the mean fluorescence intensity was slightly lower. The MFI in the table below is the mean fluorescence intensity of Cell Trace Violet in the detected cells, which decreased in proliferating cells. That is, at the same detection time, the faster the cell proliferation, the lower the mean fluorescence intensity detected.
[0154] Table 17. Proliferation of Tregs activated by IL-2 mutants detected by FACS
[0155] [Table 17]
[0156] Table 18. CD4 activated by IL-2 mutants detected by FACS + CD25 - FoxP3 - T cell proliferation
[0157] [Table 18]
[0158] Table 19. CD8 activated by IL-2 mutants detected by FACS + T CD25 - T cell proliferation
[0159] [Table 19]
[0160] Example 11. Regulatory effect of IL-2 mutants on NK cell proliferation
[0161] NK cells were sorted and counted using an NK sorting kit (purchased from Miltenyi Biotec, catalog number 130-092-657), and then resuspended in MEM medium (purchased from Gibco, catalog number 12634-010) containing 25% bovine serum (purchased from Gibco, catalog number 10099-141C), 0.2 mM inositol (purchased from Sigma-Aldrich, catalog number I7508-50G), 0.1 mM β-mercaptoethanol (purchased from Sigma-Aldrich, catalog number M3148-100ML), and 0.02 mM folic acid (purchased from Sigma-Aldrich, catalog number F8758-5G). Cells were seeded in 96-well plates with Fc blocker (purchased from BioLegend, catalog number 422302) and IL-2 mutants in each well and cultured for 3 days. BrdU (BioLegend, Cat. No. 423401) was added for the final 18 hours. Cells were harvested, washed and resuspended in PBS containing 1% BSA, fixed with an equal volume of 4% paraformaldehyde (Dingguo, Cat. No. AR-0211) at room temperature for 30 minutes, and washed with PBS containing 1% BSA. Cells were permeabilized with 0.5% Triton-X100 (Thermo Fisher, Cat. No. HFH10) at room temperature for 15 minutes, washed with PBS containing 1% BSA, and digested with DnaseI (Sigma-Aldrich, Cat. No. D4513-1VL) at 37°C for 1 hour. Cells were washed and resuspended in PBS containing 1% BSA, stained with APC anti-BrdU antibody (BioLegend, Cat. No. 339808) at room temperature for 20 minutes, and washed with PBS containing 1% BSA. The samples were resuspended in 200 μL of PBS containing 1% BSA, and detected and analyzed by FACS (FACS Canto II, purchased from BD). The results are shown in FIG. 8 and Table 20. The results show that the effect of the IL-2 mutants on the proliferation of NK cells was significantly reduced compared to wild-type IL-2. The data in Table 20 are the percentage of BrdU-positive cells in the NK cell population.
[0162] Table 20. Proliferation of NK cells activated by IL-2 mutants detected by FACS
[0163] [Table 20]
[0164] Example 12. Pharmacodynamic (PD) results in wild-type mice after subcutaneous administration
[0165] 6-8 week old female Balb / c mice were purchased from Vital River. Fc-linker-IL2_V91K and mut11.08-linker2-hFc were diluted in PBS and subcutaneously administered to the back of the mice at 200 μL per mouse. After administration, whole blood and spleen samples of the mice were collected at different time points for FACS analysis. The sequence of Fc-linker-IL2_V91K is shown in SEQ ID NO: 60 and was purified as described in Example 2. PKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINKIVLELKGSETTFMCEYADETATIVEFLNRWITFAQSIISTLT (SEQ ID NO: 60)
[0166] Mouse whole blood was collected in a 2 mL EDTA / 2K anticoagulant tube (Shinkan Medical, catalog number X424) and mixed well with the anticoagulant by tilting the tube up and down to ensure complete contact with the anticoagulant. 300 μL of whole blood was transferred to a FACS tube, and a mixed solution of staining antibodies was added and incubated at room temperature in the dark for 20 minutes. Then, red blood cell lysis buffer (Hybrimax, catalog number R7757-100 mL) (1 mL per sample) was added to the sample, and the sample was left at room temperature in the dark for 5 minutes, and a flocculent precipitate was observed. The sample was then centrifuged at 400 g for 6 minutes at 20 °C. The supernatant was discarded, and the cells were dispersed. The lysis of red blood cells was repeated. As a cell wash, the cells were resuspended in PBS (4 mL per sample) and centrifuged at 500 g for 6 minutes at 4 °C. The supernatant was discarded, and the cells were dispersed. Fixation buffer (500 μL per tube) was added dropwise to the tubes, with intermittent shaking of the FACS tubes after each addition. Samples were fixed for 1 hour or overnight at 4°C.
[0167] Mouse spleens were ground on a 70 μm cell strainer (Falcon Corning, Cat. No. 352350) and centrifuged at 500 g. 3 mL of red blood cell lysis buffer was added to each spleen and lysed for 5 min, after which lysis was stopped by adding 20 mL of PBS. The mixture was centrifuged at 500 g for 5 min. Cells were resuspended in 5 mL of PBS and screened through a 70 μm cell strainer. After cell counting, 1 × 10 cells were added to each FACS tube. 61000 cells were added. After adding Fc blocker (Biolegend, Cat. No. 156603) (5 μL per tube), the cells were vortexed and incubated at 4°C for 20 min (vortexing every 10 min). Then, FACS wash buffer (PBS + 1% BSA) (4 mL per tube) was added to the cells and centrifuged at 400g for 6 min at 4°C. The supernatant was discarded and the top of the tube was dried using blotting paper. Anti-mouse CD3e (BD Biosciences, Cat. No. 740014), anti-mouse CD4 (BD Biosciences, Cat. No. 553407), and anti-mouse CD25 (Biolegend, Cat. No. 102008) were added to the cells, vortexed, and incubated at 4°C for 20 min (vortexing every 10 min). Then, FACS wash buffer (4 mL per tube) was added to the cells and centrifuged at 400g for 6 min at 4°C. The supernatant was discarded and the tube mouth was dried using blotting paper. After vortexing once, fixation buffer (500 μL per tube) was added dropwise to the tube, with intermittent shaking of the tube after each addition. Samples were fixed at 4°C for 1 hour or overnight.
[0168] Fixation buffer was prepared by mixing Fixation / Permeabilization Concentrate and Fixation / Permeabilization Diluent from Set 3901 (eBiosciences, Cat. No. 00-5523-00) in a 1:3 ratio.
[0169] Permeabilization buffer and ddH 2Permeabilization solution was prepared by mixing 1:9 ratio of 0 and 1:10 well. Permeabilization solution (2 mL per tube) was added to the cells and centrifuged at 500g for 6 min at 4°C. The supernatant was discarded and the tube mouth was dried using blotting paper. The permeabilization process was repeated using permeabilization solution (3 mL per tube). Foxp3 antibody (eBiosciences, Cat. No. 25-5773-82) (10 μL per tube) was added to the cells and kept at 4°C for 40 min (vortexed every 20 min). Then, FACS buffer (4 mL per tube) was added to the cells and centrifuged at 500g for 6 min at 4°C. The supernatant was discarded and the tube mouth was dried using blotting paper. After vortexing once, 100 μL of FACS buffer was added to the tube to resuspend the cells for detection. Treg (CD4 + CD25 + Foxp3 + ), CD4 + CD25 - Foxp3 - T cells, and CD3 + CD4 - The percentage of T cells was expressed as the mean ± standard deviation (mean ± SEM), graphed, and analyzed using GraphPad Prism 5 software.
[0170] As shown in Figures 9A to 9C and 10A to 10C, when administered subcutaneously at a dose of 1 mpk, mut11.08-linker2-hFc significantly increased the percentage of Tregs and CD4 + CD25 - Foxp3 - Significantly reduced the percentage of T cells. + CD4 - The percentage of T cells did not change significantly. The potency of mut11.08-linker2-hFc was better than that of Fc-linker-IL2_V91K.
[0171] Example 13. Wild-type mouse DTH (delayed type hypersensitivity) model
[0172] The sensitization phase was as follows: The antigen was emulsified with 3 mg / mL KLH (Sigma, Cat. No. H7017, 50 mg), IFA (Sigma, Cat. No. F5506, 10 mL), and CFA (Sigma, Cat. No. F5581, 10 mL) in a 1:1:1 volume ratio by the double-hub needle technique. The antigen was allowed to completely emulsify to form a viscous emulsion in approximately 1 hour. Each mouse was injected with 100 μL of emulsifier, i.e., 100 μg KLH. Each mouse was injected subcutaneously with emulsified KLH at two sites (50 μL each site) in the mid-scapular region. At the same time, WT IL-2 linker2-hFc (WT IL-2, SEQ ID NO: 12), Fc-linker-IL2_V91K, or mut11.08-linker2-hFc was subcutaneously injected into mice at a dose of 1 mpk, 200 μL per mouse once every three days for the WT IL-2 linker2-hFc, Fc-linker-IL2_V91K, and mut11.08-linker2-hFc groups. Cyclosporine A (CsA, Sigma, Catalog No. F5581, 10 mL) was intraperitoneally injected into mice at a dose of 10 mpk, 200 μL per mouse once a day for the CsA group. PBS was intraperitoneally injected into mice as a vehicle control group.
[0173] The challenge was given on the fifth day after sensitization. 10 mg / mL KLH was diluted 10-fold with PBS to give 1 μg / μL. Each mouse was intradermally injected with 10 μL of KLH (i.e., 10 μg of KLH) in the right ear and 10 μL of PBS in the left ear as a control.
[0174] Before sensitization, the left and right ear thickness of each mouse was measured and recorded using a spiral micrometer (0 mm to 25 mm, accuracy: 0.001, purchased from Nanjing SuCe Measuring Instrument Co., Ltd.). Before stimulation, the left and right ear thickness of each mouse was measured using a spiral micrometer and used as the baseline value. Ear thickness was measured 24 hours, 48 hours, 72 hours, and 96 hours after stimulation. The changes in body weight and ear thickness in each group were expressed as mean ± standard deviation (mean ± SEM), graphed, and analyzed using GraphPad Prism 5 software.
[0175] The results are shown in Figure 11A. After a single subcutaneous administration of 1mpk, the change in Δ ear thickness in the WT IL-2 group was not significant compared to the vehicle control group, but the Δ ear thickness of the mice in the mut11.08-linker2-hFc group was smaller, suggesting the anti-inflammatory effect of mut11.08-linker2-hFc, which is better than that of Fc-linker-IL2_V91K and CsA. As shown in Figure 11B, there was no significant change in the body weight of the animals in each group.
[0176] The results of the second experiment are shown in Figure 12A. One dose (1mpk) of Fc-linker-IL2_V91K was administered subcutaneously, while mut11.08-linker2-hFc was administered subcutaneously at a dose of 0.04mpk, 0.2mpk, 1mpk, or 5mpk. The anti-inflammatory effect of mut11.08-linker2-hFc was dose-dependent. The effect of mut11.08-linker2-hF at 0.2mpk was similar to that of 1mpk of Fc-linker-IL2_V91K, and no abnormalities in body weight were observed under this condition. As shown in Figure 12B, when mut11.08-linker2-hFc at 5mpk was administered, the body weight of the mice fluctuated and decreased, while the body weight of the other groups was normal.
[0177] Example 14. PD results in PBMC mice after subcutaneous administration
[0178] Female NOG mice aged 11 to 12 weeks were purchased from Vital River. On day 1, PBMCs were thawed and activated by adding CD3 (purchased from eBiosciences, catalog number 16-0037-85 / 2106800, final concentration 12.5 ng / mL) and CD28 (purchased from eBiosciences, catalog number 16-0289-85 / 2073954, final concentration 25 ng / mL) and incubated overnight at 37°C in a 5% CO2 incubator for 16 hours. On day 0, PBMCs (20 × 10 per mouse) were cultured at 37°C for 16 hours. 6Each mouse was then harvested and inoculated into NOG mice via the tail vein (400 μL). Based on body weight, the inoculated mice were randomly divided into five groups, including a PBS control group, a mut11.08-linker2-hFc group (0.3 mpk, 1 mpk), and a Fc-linker-IL2_V91K group (0.3 mpk, 1 mpk), with three mice in each group. One dose of the drug was then subcutaneously injected into the neck (day 0). Three days after administration, the spleens of euthanized mice were removed for FACS analysis and the data were recorded. Treg (CD4 + CD25 + Foxp3 + ), Tcon(CD4 + CD25 - ), and CD8 + T cell numbers and fold changes were graphed and analyzed using GraphPad Prism 8 software.
[0179] The experimental results are shown in Figures 13A and 13B and Figures 14A to 14C. After a single subcutaneous administration of 1 mpk, mut11.08-linker2-hFc dose-dependently increased the ratio of Treg / Tcon and Treg / CD8 on day 3. + On the third day after administration, the number of Tcon increased but not significantly, except for the number of Treg, which changed significantly, and the number of CD8 + The number of T cells did not change significantly.
[0180] Example 15. PBMC Mouse Graft-versus-Host Disease (GVHD) Model
[0181] Female NOG mice aged 13 to 14 weeks were purchased from Vital River. The protocol was the same as in Example 14. Based on body weight, NOG mice were divided into three groups, including G1 group (PBS, no activated PBMC inoculation, 3 mice), G2 group (PBS, 10 mice), and G3 group (administered 0.2mpk mut11.08-linker2-hFc, 10 mice), where G2 and G3 groups were inoculated with activated PBMC according to Example 14. Then, one dose of drug was subcutaneously injected in the neck (day 0). Mice were weighed twice a week and scored based on the GVHD characteristics they exhibited [scoring system: weight loss (0: <10%, 1: 10%-20%, 2: >20%, 3: >30%); anemia (0: red or pink tail, 1: white tail); posture (0: normal, 1: hunched back); general activity (0: normal, 1: limited); shedding (0: no shedding, 1: shedding); and jaundice (0: white or red tail, 1: yellow tail); maximum disease severity or death corresponds to 8]. Data were recorded. Note 1: If a mouse scored at maximum severity, no other symptoms were scored; Note 2: Dead mice were continued to be scored after death until the end of the experiment.
[0182] The experimental results are shown in Figures 15A and 15B. On the 13th day after PBMC transplantation, the body weight of the G2 group had decreased, and the symptoms of GVHD appeared early in the G2 group. On the 17th day after PBMC transplantation, the body weight of the G3 group had decreased, and the overall body weight loss of the G3 group was smaller than that of the G1 group, and the weight loss of the G3 group occurred later than that of the G2 group. These results suggest that mut11.08-linker2-hFc effectively suppresses the occurrence of GVHD in mice according to pharmacological expectations. At 0.2mpk, mut11.08-linker2-hFc showed no toxic effects or side effects, and showed good anti-GVHD ability as evaluated by body weight. Furthermore, the mortality rate and GVHD score of animals in the G3 group were lower than those in the G2 group, with significant differences.
[0183] Example 16. Pharmacokinetics in mice
[0184] The method for determining mouse plasma drug concentration in this experiment is as follows: Plates were coated with 1 μg / mL hIL2R alpha protein (ACRO Biosystems, Cat. No. ILA-H52H9-100 μg). Standard curves of drugs were prepared in blank serum at concentrations ranging from 500 ng / mL to 3.90625 ng / mL. High / medium / low quality controls were prepared, and all samples to be detected, standards, and quality controls were diluted 40-fold with diluent and then added to the plate in duplicate (100 μl / well) (samples may be further diluted according to actual circumstances). Detection antibody "Peroxidase Affinipure Mouse Anti-Human IgG, Fcγ Fragment Specific" (Jackson, Cat. No. 209-035-098) was diluted 10,000-fold and then added to the plate. For color development, TMB color development solution was added to the plate (100 μl / well), and then the color development was stopped with 1 M sulfuric acid (50 μl / well).
[0185] After subcutaneous administration (1 mpk), plasma drug concentrations were determined in wild-type mice. The results of two experiments are shown in Figures 16A and 16B and Tables 21 and 22. In both experiments, the exposure of mut11.08-linker2-hFc was 4- to 6-fold higher than that of Fc-linker-IL2_V91K (control group), and T max After a single subcutaneous injection (1 mpk), the exposure of mut11.08-linker2-hFc was higher than that of mut11-linker2-hFc.
[0186] Table 21. Pharmacokinetic parameters in wild-type mice after a single subcutaneous administration.
[0187] [Table 21]
[0188] Table 22. Pharmacokinetic parameters in wild-type mice after a single subcutaneous administration.
[0189] [Table 22]
[0190] After intravenous administration (1 mpk), plasma drug concentrations were determined in wild-type mice. The results are shown in Figure 17 and Table 23. The exposure of mut11.08-linker2-hFc was higher than that of Fc-linker-IL2_V91K, but the difference was smaller compared to subcutaneous administration (C max : 3× → 1.3×, AUC: 4× → 2.4×). The exposure of mut11.08-linker2-hFc was higher than that of mut11-linker2-hFc, but the difference was smaller compared to subcutaneous administration (C max :2.4×→1.2×, AUC:3.2×→1.6×).
[0191] Thus, the bioavailability of subcutaneously administered mut11.08-linker2-hFc was better than that of Fc-linker-IL2_V91K and mut11-linker2-hFc. Stabilizing mutations increased drug exposure and bioavailability.
[0192] Table 23. Pharmacokinetic parameters in wild-type mice after a single intravenous administration.
[0193] [Table 23]
[0194] Mice were inoculated with PBMCs as described in Example 14. Plasma drug concentrations were determined in wild-type mice after a single subcutaneous dose (1 mpk). The results are shown in Figure 18 and Table 24. In PBMC mice, the exposure of mut11.08-linker2-hFc was 5- to 8-fold higher than that of Fc-linker-IL2_V91K after a single subcutaneous dose (1 mpk), demonstrating a clear advantage in the T of mut11.08-linker2-hFc. max Fc-linker-IL2_V91K T maxIt was slower than that.
[0195] Table 24. Pharmacokinetic parameters in PBMC mice after a single subcutaneous administration
[0196] [Table 24]
[0197] Example 17. Pharmacokinetic and PD results in cynomolgus monkeys
[0198] The method for determining cynomolgus monkey plasma drug concentrations in this experiment is as follows: Plates were coated with 1 μg / mL hIL2R alpha protein (ACRO Biosystems, Cat. No. ILA-H52H9-100 μg). A standard curve of the drug was generated in blank serum from cynomolgus monkeys, ranging from 15 ng / mL to 0.11718 ng / mL. High / medium / low quality controls were prepared and all samples to be detected, standards, and quality controls were diluted 5-fold and then added to the plate in duplicate (100 μl / well). The detection antibody "Goat Anti-Human IgG, Monkey ads-BIOT" (Southern Biotech, Cat. No. 2049-08) was diluted 1000-fold before being added to the plate, followed by 5000-fold diluted streptavidin-HRP (Thermo, Cat. No. 21126) to the plate. Finally, for color development, TMB color development solution was added (100 μl / well), and then 1 M sulfuric acid (50 μl / well) was used to stop the color development. Cynomolgus monkey blank serum was purchased from Shanghai Hkey Biotechnology Co., Ltd.
[0199] IL-2 was administered subcutaneously to four cynomolgus monkeys at a dose of 0.05mpk. One of them received WT IL-2-linker2-hFc (abbreviated as WT IL-2, shown in SEQ ID NO: 12), one received Fc-linker-IL2_V91K, and two received mut11.08-linker2-hFc (abbreviated as Mut11.08-1 and Mut11.08-2, respectively), and plasma drug concentrations were detected after administration. The results are shown in Figure 19 and Table 25. At a dose of 0.05mpk, the WT IL-2 molecule had a long terminal half-life, while the terminal half-lives of Fc-linker-IL2_V91K and mut11.08-linker2-hFc were similar. max and the rank order of AUC was mut11.08-linker2-hFc>Fc-linker-IL2_V91K>WT IL2.
[0200] Table 25. Pharmacokinetic parameters in cynomolgus monkeys after a single subcutaneous administration.
[0201] [Table 25]
[0202] Four cynomolgus monkeys were used to determine the effect of a single subcutaneous injection of mut11.08-linker2-hFc on the proliferation of cynomolgus-derived Tregs. One received WT IL-2-linker2-hFC, one received Fc-linker-IL2_V91K, and the other two received mut11.08-linker2-hFc. Each was administered a dose of 0.05 mpk (single subcutaneous injection). Peripheral blood from cynomolgus monkeys was collected before administration and on days 1, 3, 5, 7, 10, and 14 after administration. PBMCs were isolated and frozen from 2 mL cynomolgus blood samples collected at different time points. Vials of frozen PBMCs from each time point were removed and thawed together for analysis. Thawed PBMCs were resuspended in 1 mL of staining buffer (DPBS buffer containing 2% FBS) and then 200 μL each was transferred to two 96-well V-bottom plates, Panel 1 and Panel 2. The two plates were washed once with PBS and then stained with Live / Dead Fixable Near-IR (Thermo, Cat. No. 134976) for 20 min. After stopping the staining with staining buffer, Human True Stain FcX (Biolegend, Cat. No. 422302) was added to the plates and incubated for 20 min. The two plates were then stained with a mixture of different fluorescent antibodies for 30 min. For panel 1, BV605 mouse anti-human CD3 (BD Catalog No. 562994), PerCP-Cy5.5 mouse anti-human CD4 (BD Catalog No. 552838), FITC mouse anti-human CD8 (Biolegend Catalog No. 301050), and BV421 mouse anti-human CD25 (Biolegend Catalog No. 302630) were diluted in Brilliant Stain Buffer (BD Catalog No. 563794). For panel 2, BV605 mouse anti-human CD3 (BD, catalog no. 562994), PerCP-Cy5.5 mouse anti-human CD4 (BD, catalog no. 552838), FITC mouse anti-human CD8 (Biolegend, catalog no. 301050), and Brilliant Violet 421 anti-human CD16 (Biolegend, catalog no. 302038) were diluted in Brilliant Stain Buffer.After staining was stopped, cells were washed once and fixed and permeabilized with Foxp3 / Transcription Factor Staining Buffer Kit (eBiosciences, Cat. No. 00-5523-00). A mixture of different fluorescent antibodies was added to two plates and cells were stained for 45 minutes. In panel 1, PE anti-human FOXP3 (BioLegend, Cat. No. 320208) and Ki67 monoclonal antibody APC (eBiosciences, Cat. No. 17-5698-82) were diluted in permeabilization buffer. In panel 2, Ki67 monoclonal antibody APC was diluted in permeabilization buffer. After staining, cells were washed once with permeabilization buffer and resuspended in 400 μL staining buffer, after which 200 μL of sample was analyzed by FACS. Treg, CD4 in animal groups. + Foxp3 - T cells, CD8 + T cell and NK cell numbers and fold changes were graphed and analyzed using GraphPad Prism 9 software.
[0203] The experimental results are shown in Figures 20A to 20F. After a single subcutaneous administration (0.05 mpk), mut11.08-linker2-hFc increased the number and percentage of Tregs in the peripheral blood of cynomolgus monkeys. Treg / CD4 + According to the ratio of Tregs, mut11.08-linker2-hFc favored the activation of Tregs, so that the percentage of Tregs was about twice that of Fc-linker-IL2_V91K. Compared to Fc-linker-IL2_V91K, mut11.08-linker2-hFc was more effective in improving Treg proliferation (11.08 vs. Fc-linker-IL2_V91K, 79 / 55 vs. 18), while Fc-linker-IL2_V91K was better than WT in this respect (18 vs. 9.5). Analysis of Treg activation markers showed that after administration of the different molecules, Ki67 + There was little difference in the percentage of Tregs. The expression of Treg activation markers (Foxp3 and CD25) was significantly increased, which positively correlated with the level of Treg proliferation.
[0204] As shown in Figures 21A to 21F, after a single subcutaneous administration of Fc-linker-IL2_V91K (0.05 mpk), FoxoP3 - CD4 + The maximum fold change in T cells was approximately 2-fold, whereas CD8 + In T cells, it was slightly higher, about four times higher. - CD4 + The effect of mut11.08-linker2-hFc on T cell proliferation was approximately 2- to 3-fold stronger than that of Fc-linker-IL2_V91K, whereas the ... + The effect on T cell proliferation was similar to or slightly weaker than that of Fc-linker-IL2_V91K, being approximately 1.5 to 2 times that of WT. The number of NK cells did not change significantly after administration of Fc-linker-IL2_V91K. The effect of mut11.08-linker2-hFc on the level of NK proliferation was similar to that of Fc-linker-IL2_V91K.
Claims
1. contains Y31V, A73L, H79Q, and V91R compared to wild-type IL-2; The wild-type IL-2 has the amino acid sequence shown in SEQ ID NO: 60 or SEQ ID NO:
1. IL-2 mutants.
2. The IL-2 mutant of claim 1, wherein the IL-2 mutant has the amino acid sequence shown in SEQ ID NO:
32.
3. The IL-2 mutant of claim 1, wherein the Tm value of the IL-2 mutant is higher than the Tm value of the wild-type IL-2.
4. The IL-2 mutant according to any one of claims 1 to 3, wherein the IL-2 mutant has a reduced ability to bind to the IL-2Rβγ subunit complex compared to the wild-type IL-2.
5. The IL-2 mutant has a reduced ability to stimulate non-regulatory T cells or NK (natural killer) cells compared to wild-type IL-2; the stimulation can be selected from intracellular STAT5 phosphorylation or cell proliferation; 4. An IL-2 variant according to any one of claims 1 to 3, wherein the variant preferentially stimulates regulatory T cells (Treg) or T cell populations in peripheral blood over non-regulatory T cells or NK (natural killer) cells; the preferential stimulation may be selected from preferentially stimulating STAT5 phosphorylation in regulatory T cells, preferentially stimulating proliferation of regulatory T cells, increasing the ratio of regulatory T cells to non-regulatory T cells, or increasing the ratio of regulatory T cells to NK cells.
6. A fusion protein comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is an IL-2 mutant of claim 1 and the second polypeptide is an Fc.
7. The fusion protein described in claim 6, wherein the Fc is an Fc of human IgG.
8. The human IgG Fc is a human IgG1 Fc, the human IgG1 Fc comprises the mutations C220S and N297G; The fusion protein of claim 7.
9. the C-terminus of the first polypeptide is linked to the N-terminus of the second polypeptide via a linker; The linker is 4 S) n , (GGNGT) n , or (YGNGT) n 9. The fusion protein of claim 6, wherein n is selected from 1, 2, 3, 4, or 5.
10. The fusion protein of any one of claims 6 to 8, wherein the fusion protein comprises the amino acid sequence shown in SEQ ID NO:
50.
11. A pharmaceutical composition comprising an IL-2 variant according to any one of claims 1 to 5 or a fusion protein according to any one of claims 6 to 10, and a pharma- ceutically acceptable carrier, diluent or adjuvant; The pharmaceutical composition is a pharmaceutical composition for intravenous or subcutaneous injection.
12. Use of an IL-2 variant according to any one of claims 1 to 5 or a fusion protein according to any one of claims 6 to 10 in the manufacture of a medicament for the treatment of a disease, comprising The drug is an injectable drug; The medicament is used to treat an autoimmune disease; The autoimmune disease comprises rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, IgA nephropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, psoriasis, plaque psoriasis, alopecia areata, multiple sclerosis, amyotrophic lateral sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft versus host disease, organ transplant rejection, autoimmune hepatitis, type I diabetes, autoimmune vasculitis, eczema, or asthma.
Citation Information
Patent Citations
Long-acting interleukin-2 capable of realizing targeted regulation of T cell, and application of long-acting interleukin-2 for treating autoimmunity disease
CN110642934A
Mutant interleukin-2 (IL-2) polypeptides
US20050142106A1
